Summary
Researchers highlight the therapeutic potential of Portulaca oleracea L. (POL) in treating inflammatory conditions of the digestive system, such as non-alcoholic steatohepatitis (NASH) and gastritis. Active compounds in POL, such as kaempferol, luteolin, and quercetin, have demonstrated anti-inflammatory and anticancer effects. The review points out that these compounds may improve NASH and its complications, as well as gastritis and gastric cancer. Despite promising results, research still lacks clinical data to prove the mechanisms of action of POL compounds and their pharmacokinetics in humans. Additional studies on the hepatic and renal toxicity of POL are also necessary to validate its use in clinical practice. POL, with its rich chemical composition, including flavonoids and organic acids, emerges as a promising candidate for the prevention and treatment of inflammation-related cancers in the digestive system.
Key points
- Kaempferol and luteolin have been shown to improve non-alcoholic steatohepatitis (NASH) and its complications.
- Compounds such as quercetin and apigenin have therapeutic effects on gastritis and gastric cancer.
- Portulaca oleracea L. contains flavonoids and other compounds that exhibit anti-inflammatory and anticancer properties.
- There is a lack of clinical data on the pharmacokinetics and mechanisms of action of the active compounds in POL.
- Studies on the hepatic and renal toxicity of POL are necessary to validate its clinical use.
✦ For you
If you are interested in digestive health, consider including Portulaca oleracea in your diet, whether as a salad or tea. Observe how your body reacts and if there are improvements in digestion or reductions in inflammation. Remember that it is important to consult a qualified healthcare professional if symptoms persist.
For practitionersExpand
In clinical practice, consider including Portulaca oleracea (POL) in protocols for patients with inflammatory conditions of the digestive system. Assess patient responses to the use of POL and adjust formulations as necessary, taking into account the identified active compounds, such as kaempferol and luteolin. Be aware of the need for more studies on the toxicity and clinical efficacy of POL.